327 related articles for article (PubMed ID: 27670779)
1. Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer.
Skouras VS; Maragkos C; Grapsa D; Syrigos KN
BioDrugs; 2016 Oct; 30(5):421-439. PubMed ID: 27670779
[TBL] [Abstract][Full Text] [Related]
2. Targeting angiogenesis in squamous non-small cell lung cancer.
Piperdi B; Merla A; Perez-Soler R
Drugs; 2014 Mar; 74(4):403-13. PubMed ID: 24578213
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy.
Rossi A; Maione P; Sacco PC; Ambrosio R; Falanga M; Gridelli C
Curr Drug Targets; 2010 Jul; 11(7):865-8784. PubMed ID: 20412044
[TBL] [Abstract][Full Text] [Related]
4. The role of anti-angiogenesis in non-small-cell lung cancer: an update.
Villaruz LC; Socinski MA
Curr Oncol Rep; 2015 Jun; 17(6):26. PubMed ID: 25947099
[TBL] [Abstract][Full Text] [Related]
5. Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analyses.
Liang W; Wu X; Hong S; Zhang Y; Kang S; Fang W; Qin T; Huang Y; Zhao H; Zhang L
PLoS One; 2014; 9(10):e109757. PubMed ID: 25329056
[TBL] [Abstract][Full Text] [Related]
6. Targeting tumor neovasculature in non-small-cell lung cancer.
Pallis AG; Syrigos KN
Crit Rev Oncol Hematol; 2013 May; 86(2):130-42. PubMed ID: 23159217
[TBL] [Abstract][Full Text] [Related]
7. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions.
Ellis PM; Al-Saleh K
Crit Rev Oncol Hematol; 2012 Oct; 84(1):47-58. PubMed ID: 22405734
[TBL] [Abstract][Full Text] [Related]
8. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
[TBL] [Abstract][Full Text] [Related]
9. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
Kurzrock R; Stewart DJ
Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
[TBL] [Abstract][Full Text] [Related]
10. Targeting blood vessels for the treatment of non-small cell lung cancer.
Amir E; Hughes S; Blackhall F; Thatcher N; Ostoros G; Timar J; Tovari J; Kovacs G; Dome B
Curr Cancer Drug Targets; 2008 Aug; 8(5):392-403. PubMed ID: 18690845
[TBL] [Abstract][Full Text] [Related]
11. Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer.
Scagliotti G; Govindan R
Oncologist; 2010; 15(5):436-46. PubMed ID: 20427383
[TBL] [Abstract][Full Text] [Related]
12. Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment.
Epstein Shochet G; Israeli-Shani L; Koslow M; Shitrit D
Lung Cancer; 2016 Jun; 96():7-14. PubMed ID: 27133742
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Subramanian J; Morgensztern D; Govindan R
Clin Lung Cancer; 2010 Sep; 11(5):311-9. PubMed ID: 20837456
[TBL] [Abstract][Full Text] [Related]
14. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
Janning M; Loges S
Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer.
Huang Y; Carbone DP
Biochim Biophys Acta; 2015 Apr; 1855(2):193-201. PubMed ID: 25598052
[TBL] [Abstract][Full Text] [Related]
16. Nintedanib for the treatment of non-small-cell lung cancer.
Rashdan S; Hanna N
Expert Opin Pharmacother; 2014 Apr; 15(5):729-39. PubMed ID: 24597846
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib in non-small cell lung cancer: from preclinical to approval.
Caglevic C; Grassi M; Raez L; Listi A; Giallombardo M; Bustamante E; Gil-Bazo I; Rolfo C
Ther Adv Respir Dis; 2015 Aug; 9(4):164-72. PubMed ID: 25855060
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic therapy in nonsmall cell lung cancer.
Gutierrez M; Giaccone G
Curr Opin Oncol; 2008 Mar; 20(2):176-82. PubMed ID: 18300767
[TBL] [Abstract][Full Text] [Related]
19. Emerging angiogenesis inhibitors for non-small cell lung cancer.
Malapelle U; Rossi A
Expert Opin Emerg Drugs; 2019 Jun; 24(2):71-81. PubMed ID: 31092048
[No Abstract] [Full Text] [Related]
20. Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer.
Nguewa PA; Calvo A; Pullamsetti SS; Banat GA; Grimminger F; Savai R
Expert Opin Investig Drugs; 2011 Jan; 20(1):61-74. PubMed ID: 21142806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]